2026.06.23
On June 23, 2026, HJ Science (Chengdu) Technology (HJ Science, stock code: 06132.HK) was listed on the Main Board of the Hong Kong Stock Exchange under Chapter 18A of the Listing Rules. The company offered 13,600,000 H shares globally (subject to a 15% over-allotment option), priced at HKD 81.80 per share and raised approximately HKD 1.112 billion. JunHe acted as the issuer's PRC legal advisor for this project.
Founded in 2017, HJ Science is a clinical-stage biotechnology company that develops therapies for autoimmune, metabolic and oncological diseases. Its R&D pipeline includes three core products, HJ787, HJ178 and HJ891, as well as several clinical-stage and preclinical candidate drugs. All core products are self-developed, small-molecule, Category 1 innovative drugs approved by the National Medical Products Administration (NMPA), including:
HJ787 is a selective TYK2 inhibitor and is used for the topical treatment of mild to moderate atopic dermatitis (AD), mild to moderate acne vulgaris (AV), neurodermatitis (ND), and psoriasis (Ps) as well as oral treatment for AD, ND and Ps.
HJ178 is an orally administered drug targeting GLP-1 and GIP and is used for treating type 2 diabetes and potentially overweight or obese patients in the metabolic category.
HJ891 is an oral KRAS G12C inhibitor used for treating non-small cell lung cancer (NSCLC) with KRAS G12C mutation that has progressed after first-line standard therapy (as a monotherapy) and non-squamous NSCLC with KRAS G12C mutation (as a first-line combination therapy).
Since 2023, JunHe has served as HJ Science's legal advisor and provided legal services in areas such as restructuring, private equity financing and Hong Kong IPOs. This includes: (1) as the PRC lawyer for the Hong Kong IPO, we assisted the company in restructuring to establish a joint-stock company, issued PRC legal opinions and drafted, reviewed and amended the application and issuance documents related to the listing. JunHe prepared a full set of legal documents for the China Securities Regulatory Commission (CSRC) overseas listing filing and assisted in responding to feedback from the CSRC, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange regarding the listing application; (2) as the financing lawyer, we participated in the drafting, negotiation, signing and closing of multiple rounds of private equity financing transactions and assisted the company in completing the latest round of financing with a post-investment valuation of RMB 2.7 billion; (3) as the long-term legal advisor we also provided legal consulting services for the company's daily operations.
The partners responsible for this project were TAO, Xudong and ZHANG, Tao. The internal review partner was YAO, Jiwei (Jervis).